June 30, 2010 – (Carlsbad, CA) Etaluma, Inc. today announced that the U.S. Patent and Trademark Office has issued a patent, No. 7,700,928, to Etaluma, Inc. from its acquisition from Amgen, Inc. relating to the company’s FlashFluor cell-based screening platform.
The FlashFluor system now available commercially through Etaluma, Inc. is a 96/384/1536 well pipettor and imaging plate reader, capable of concurrent liquid transfers and kinetic fluorescence and/or luminescence measurements. It can rapidly interleave fluorescence and luminescence reads resulting in multiplexed screening and assays. FlashFluor uses best-in-class commercial components and patented optics for spectrally pure and spatially uniform excitation and detection. By switching filters and camera sensitivity settings very rapidly, it can capture multiple optical signals with sub-second sampling. It is ideal for measuring intracellular calcium dynamics, ion channel and GPCR activation, protein expression, receptor recycling, and other transient cellular events coupled to optical signals. FlashFluor can detect bioluminescence from aequorin or luciferase interleaved with fluorescence from Fluo-4, GFP, or other dyes.
About Etaluma, Inc.
Etaluma, Inc. is an early-stage bio-analytical instrumentation company focused on the development of low-cost, simple, and accessible products. Founded in early 2009, Etaluma is headquartered in Carlsbad, CA. For more information, visit www.etaluma.com.